Christopher Wenger, DO
Cardiovascular Disease · York, PANPI 1861650772
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,071 of the $90,501 with a category attached, or 80.7%. 9 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 54.9% of the total. Reporting peaked in 2022 at $27,060 and has fallen 86.9% since, to $3,555 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $628.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$50K
- Amgen$23K
- Novartis$10K
- Amarin Pharma, Inc.$7K
- Sanofi-aventis U.S. LLC$125
- AstraZeneca$108
- plus $66 from 3 others
Across 6 payments — averaging $78,452 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$471K
What the payments were for
- Consulting fees$1,9002%
- Speaking & faculty fees$73,07181%
- Travel & lodging$12,10313%
- Food & beverage$3,4124%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 67 | $49,688 |
| Amgen | 44 | $23,109 |
| Novartis | 16 | $10,307 |
| Amarin Pharma, Inc. | 10 | $7,099 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| AstraZeneca | 1 | $108 |
| Pfizer | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,501 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 347 | $294,638 |
| EliquisApixaban | 74 | $76,737 |
| Praluent PenAlirocumab | 93 | $57,069 |
| JardianceEmpagliflozin | 17 | $26,976 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $26,641 |
| Repatha PushtronexEvolocumab | 14 | $13,165 |
| Ezetimibe | 418 | $12,093 |
| Repatha SyringeEvolocumab | 11 | $10,453 |
| Icosapent Ethyl | 14 | $5,460 |
| VascepaIcosapent Ethyl | 11 | $5,189 |
| Rosuvastatin Calcium | 449 | $4,232 |
| Atorvastatin Calcium | 220 | $1,890 |
| Metoprolol Succinate | 168 | $1,773 |
| Omega-3 Acid Ethyl Esters | 18 | $1,448 |
| ClopidogrelClopidogrel Bisulfate | 60 | $1,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $76,73774 claims |
| Esperion Therapeutics, Inc.Nexlizet | $49,688 | $26,64123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in York
- Rhian DaviesYork$853K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.